"Tell juliana": Acceptability of the candidate microbicide vivagel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study

AIDS and Behavior

Volumn 16, Issue 7, 2012, Pages 1761-1774

  Carballo Diéguez, Alex ^a   Giguere, Rebecca ^a   Dolezal, Curtis ^a   Chen, Beatrice A ^b,c   Kahn, Jessica ^d   Zimet, Greg ^e   Mabragaña, Marina ^a   Leu, Cheng Shiun ^a   Mc Gowan, Ian ^b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

HEC; HIV prevention; Leakage; Microbicide acceptability

Indexed keywords

DENDRIMER; PLACEBO; POLYLYSINE; TOPICAL ANTIINFECTIVE AGENT; VIVAGEL;

ADOLESCENT; ADULT; ARTICLE; CONSUMER; ETHNOLOGY; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; INTRAVAGINAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PHASE 1 CLINICAL TRIAL; PUERTO RICO; QUALITATIVE RESEARCH; QUESTIONNAIRE; SEXUAL BEHAVIOR; SOCIOECONOMICS; STATISTICAL MODEL; UNITED STATES;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ANTI-INFECTIVE AGENTS, LOCAL; CONSUMER SATISFACTION; DENDRIMERS; FEMALE; GELS; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; PATIENT ACCEPTANCE OF HEALTH CARE; PLACEBOS; POLYLYSINE; PUERTO RICO; QUALITATIVE RESEARCH; QUESTIONNAIRES; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84868485927     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0028-6     Document Type: Article

References (20)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74
2. Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319-30
3. Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2008;3(5):581-6
4. Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9(1):121-31
5. Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12(2): 272-83
6. Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plan Perspect. 2000;32(4):184-8
7. Rosen RK, Morrow KM, Carballo-Diéguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health. 2008;17(3): 383-92
8. Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006; 20(17):2141-8
9. Joglekar N, Joshi S, Kakde M, et al. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care. 2007;19(6):817-21
10. Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health. 2003;12(7): 655-66
11. Mason TH, Foster SE, Finlinson HA, et al. Perspectives related to the potential use of vaginal microbicides among drug-involved women: focus groups in three cities in the United States and Puerto Rico. AIDS Behav. 2003;7(4):339-51
12. Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94(7):1159-64
13. McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel-) in sexually active young women (MTN-004). AIDS. 2011;25(8):1057-64
14. SPSS Inc. SPSS for Windows, Rel. 17.0.0.2008. Chicago, IL
15. Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5
16. Jenness SM, Begier EM, Neaigus A, Murrill CS, Wendel T, Hagan H. Unprotected anal intercourse and sexually transmitted diseases in high-risk heterosexual women. Am J Public Health. 2011;101(4):745-50
17. Maynard E, Carballo-Diéguez A, Ventuneac A, Exner T, Mayer K. Women's experiences with anal sex: motivations and implications for STD prevention. Perspect Sex Reprod Health. 2009;41(3):142-9
18. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148(1): 88-96
19. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999;13(2): 155-66
20. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10(Suppl A):S75-82